1st Quarter - Termination

MEDCO HEALTH SOLUTIONS, INC for MEDCO HEALTH SOLUTIONS INC

Firm
Client
Income
—
Expenses
$1,050,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Mar 31, 2012

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Regulatory policies related to health reform implementation; structure, drug benefits, disclosure; regulatory implementation of HITECH, Medicare Part-D, Accounting of Disclosures; FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMS)

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN —
PETER HARTY —
DOLLY JUDGE —
RYAN SADLER —

Contacted: SENATE; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D; healthcare regulations; closing of the Part D coverage gap; IVIG payment structure; Medicar demonstration projects for durable medical equipment; home infusion; PBM disclosure provisions; increasing healthcare value; competitive bidding (H.R. 2195, S. 1203, H.R. 1845, S. 960, H.R. 979, H.R. 1041)

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN —
PETER HARTY —
DOLLY JUDGE —
RYAN SADLER —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP)

Bills named: H.R. 1041 (112th), H.R. 979 (112th), H.R. 1845 (112th), S. 1203 (112th), H.R. 2195 (112th), S. 960 (112th)

Pharmacy PHA

Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (EHB, grandfathering, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway to approve biosimilars; REMs; proposed antitrust exemptions for certain pharmacies; 340b program

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN —
PETER HARTY —
DOLLY JUDGE —
RYAN SADLER —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 27 (112th)

Postal POS

Legislation related to mail delivery frequency (The Postal Reform Act; U.S. Postal Improvements Act; Postal Operations Sustainment and Transformation Act; and 21st Century Postal Service Act)

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from antitrust laws for purposes of negotiating with payers (H.R. 1409, H.R. 1946, H.R. 1839). Advocacy surrounding proposed corporate merger.

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN —
PETER HARTY —
DOLLY JUDGE —
RYAN SADLER —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP)

Bills named: H.R. 1946 (112th), H.R. 1409 (112th), H.R. 1839 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.